Tassone P - Search Results

1

Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.

Tagliaferri P, Tassone P, Blotta S, Viscomi C, Grillone F, Budillon A, Caraglia M, Venuta S. Tagliaferri P, et al. Among authors: tassone p. Curr Drug Targets. 2005 May;6(3):289-300. doi: 10.2174/1389450053765897. Curr Drug Targets. 2005. PMID: 15857289 Review.

2

Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.

Tassone P, Tagliaferri P, Rossi M, Calimeri T, Bulotta A, Abbruzzese A, Caraglia M, Neri P. Tassone P, et al. Curr Cancer Drug Targets. 2009 Nov;9(7):854-70. doi: 10.2174/156800909789760393. Curr Cancer Drug Targets. 2009. PMID: 20025573 Review.

3

Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.

Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P. Tassone P, et al. Curr Cancer Drug Targets. 2012 Sep;12(7):814-22. doi: 10.2174/156800912802429292. Curr Cancer Drug Targets. 2012. PMID: 22671927 Free PMC article. Review.

4

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.

Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, Martelli ML, Goel A, Barbieri V, Costanzo F, Boland CR, Venuta S. Tassone P, et al. Br J Cancer. 2003 Apr 22;88(8):1285-91. doi: 10.1038/sj.bjc.6600859. Br J Cancer. 2003. PMID: 12698198 Free PMC article.

5

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR, Venuta S. Tassone P, et al. Br J Cancer. 2003 Jun 16;88(12):1971-8. doi: 10.1038/sj.bjc.6600986. Br J Cancer. 2003. PMID: 12799645 Free PMC article.

6

Targeting Raf-kinase: molecular rationales and translational issues.

Caraglia M, Tassone P, Marra M, Budillon A, Venuta S, Tagliaferri P. Caraglia M, et al. Among authors: tassone p. Ann Oncol. 2006 Jun;17 Suppl 7:vii124-7. doi: 10.1093/annonc/mdl964. Ann Oncol. 2006. PMID: 16760274 Free article. Review.

7

Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.

Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M. Marra M, et al. Among authors: tassone p. Curr Cancer Drug Targets. 2009 Nov;9(7):791-800. doi: 10.2174/156800909789760285. Curr Cancer Drug Targets. 2009. PMID: 20025567 Review.

8

Promises and challenges of MicroRNA-based treatment of multiple myeloma.

Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P. Tagliaferri P, et al. Among authors: tassone p. Curr Cancer Drug Targets. 2012 Sep;12(7):838-46. doi: 10.2174/156800912802429355. Curr Cancer Drug Targets. 2012. PMID: 22671926 Free PMC article. Review.

9

Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta).

Tassone P, Tagliaferri P. Tassone P, et al. Curr Cancer Drug Targets. 2012 Sep;12(7):741-2. doi: 10.2174/156800912802429328. Curr Cancer Drug Targets. 2012. PMID: 22934915 No abstract available.

10

Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death.

Tassone P, Tagliaferri P, Galea E, Palmieri C, Bonelli P, Martelli ML, Tuccillo F, Turco MC, Venuta S. Tassone P, et al. Eur J Cancer. 2002 May;38(8):1141-7. doi: 10.1016/s0959-8049(02)00017-5. Eur J Cancer. 2002. PMID: 12008204

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters